CYDY Stock Price: CytoDyn Inc set to skyrocket as Phase 2 coronavirus cure trial looks promising

OTCMKTS: CYDY stock may surge after reporting significant results from a COVID-19 cure trial.
CytoDyn is at an advanced stage, completing Phase 2 and may enter Phase 3 with its leronlimab medication.
Competition is fierce and attention is growing after Russia registered its first coronavirus vaccine.

Yohay Elam FXStreet

CytoDyn, a biotechnology company that spans the border between Canada and the US around Vancouver and Washington, announced a promising development. Its Phase 2 trial for COVID-19 has shown significant top-line results, opening the door to conducting a broad Phase 3 trial.

The leronlimab drug helps mild to moderate COVID-19 patients, that show an improvement in clinical symptoms versus the

From the firm's announcement:

Primary endpoint shows early clinical improvement in symptom score at Day 3 in patients receiving leronlimab

Leronlimab also demonstrated statistically significant improvement versus placebo in key secondary efficacy endpoint, National Early Warning Score 2 scale (NEWS2)

Earlier in the day, Russia's President Vladimir Putin announced that his country reported the first coronavirus vaccine. However, many doubt that Moscow's announcement is based on a rigorous experiment.

cytodyn inc Stock

OTCMKTS: CYDY

Author

Yohay Elam

FXStreet

Yohay is in Forex since 2008 when he founded Forex Crunch, a blog crafted in his free time that turned into a fully-fledged currency website later sold to Finixio.

AUD/USD bounces off multi-month low, nears 0.6900

AUD/USD edges higher toward 0.6900 in the Asian session on Wednesday, recovering some of the previous day’s losses to its lowest level since March as the US Dollar stalls the hot US CPI-inspired rally amid hopes of a US-Iran peace deal. Meanwhile, hawkish comments from FOMC members have almost confirmed another December rate hike, which favors USD bulls and should cap the Aussie.

USD/JPY remains capped below 159.00 amid looming intervention risks

USD/JPY struggles to build on the previous day’s strong gains to a near one-month top as intervention risk supports the Japanese Yen while hopes of a US-Iran peace deal cap the safe-haven US Dollar. That keeps the pair's upside limited below 159.00, for now.

Gold puts the $4,000 mark to the test

Gold now accelerates its daily correction, challenging the key $4,000 mark per troy ounce on Wednesday. The precious metal’s continuation of the downward trend comes against the backdrop of a robust performance of the US Dollar, rising US Treasury yields across the board and rising bets of extra rate hikes by the Fed.

Crypto Today: Bitcoin, Ethereum and XRP struggle to find footing amid spot ETF outflows

Cryptocurrency prices are broadly consolidating near key lower support levels on Wednesday, led by Bitcoin, hovering around $74,000. Ethereum sits above $2,000 while its upside remains structurally capped. Ripple, meanwhile, holds delicately above $1.00.

Ten questions for China in 2027

2026 has been a year of slowing growth and increasing divergence within China's economy. We saw the gap between external and domestic demand, as well as between the new economy and the old economy, widen significantly. Here, we look ahead to the key questions facing China in 2027.

What the US CPI headline doesn’t tell you about inflation

Brent crude has fallen about a third since mid-October on hopes the Iran war is ending, but diesel, freight and fertiliser costs haven't followed. Those costs reach US consumer prices in stages through 2027 and could keep inflation high after gasoline gets cheaper.